Regen Biologics Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Regen Biologics Inc.
Conflicts Of Interest Delay Leqembi’s EU Approval
Eisai/Biogen’s Alzheimer’s drug has fallen foul of a recent court ruling over the handling of the European Medicines Agency’s experts' competing interests.
Leqembi’s EU Approval Process Delayed Over Advisory Group COI Considerations
The EU regulatory agency’s discussions for lecanemab’s approval are hit by a decision to annul advice from an advisory committee due to the implications of a Court of Justice ruling on the handling of experts' competing interests.
Innovation Is Alive And Well In Sports Medicine
The sports medicine market comprises a number of product segments, many of which span several different orthopedics specialties.This space is expected to experience strong growth going forward as companies develop innovative ways, including some lower-cost approaches, to treat the joint and soft-tissue injuries commonly suffered by athletes and other sports enthusiasts.
Washington Roundup, March 2012
The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we cover FDA’s proposed comprehensive postmarket surveillance strategy, as well as updates on proposed 510(k) reforms and device user fees.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
-
- RBio, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice